Roche Diagnostics and Nordic Bioscience strengthen biomarker partnership

CEO Morten Karsdal calls it ”an important step” for Nordic Bioscience to collaborate on finding chronic disease biomarkers alongside Roche Diagnostics.


Roche Diagnostics and Nordic Bioscience have taken the next step in their partnership centered on the development of proprietary biomarkers involved in tissue breakdown and build-up, the latter firm has announced in a press release.

Nordic Bioscience develops Extracellular Matrix (ECM) biomarkers and will, under the expanded collaboration, transfer its blood-based biomarkers to Roche Diagnostics’s automated Cobas platform. According to the statement, this ”will facilitate better clinical decisions in drug development and patient selection as well as enrichment for precision medicine and ultimately improve patient outcomes.”

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs